regulatory science
Recently Published Documents


TOTAL DOCUMENTS

409
(FIVE YEARS 120)

H-INDEX

25
(FIVE YEARS 6)

2022 ◽  
pp. 2100073
Author(s):  
Pejman Ghelich ◽  
Mehdi Kazemzadeh-Narbat ◽  
Alireza Hassani Najafabadi ◽  
Mohamadmahdi Samandari ◽  
Adnan Memić ◽  
...  

2021 ◽  
Vol 31 (4) ◽  
pp. 257-267
Author(s):  
Jaehong Park ◽  
Hocheol Shin ◽  
Jiwon Kim ◽  
Minsu Kim ◽  
In Gu Do ◽  
...  
Keyword(s):  

2021 ◽  
pp. 153537022110522
Author(s):  
Elke Anklam ◽  
Martin Iain Bahl ◽  
Robert Ball ◽  
Richard D Beger ◽  
Jonathan Cohen ◽  
...  

There is an evolution and increasing need for the utilization of emerging cellular, molecular and in silico technologies and novel approaches for safety assessment of food, drugs, and personal care products. Convergence of these emerging technologies is also enabling rapid advances and approaches that may impact regulatory decisions and approvals. Although the development of emerging technologies may allow rapid advances in regulatory decision making, there is concern that these new technologies have not been thoroughly evaluated to determine if they are ready for regulatory application, singularly or in combinations. The magnitude of these combined technical advances may outpace the ability to assess fit for purpose and to allow routine application of these new methods for regulatory purposes. There is a need to develop strategies to evaluate the new technologies to determine which ones are ready for regulatory use. The opportunity to apply these potentially faster, more accurate, and cost-effective approaches remains an important goal to facilitate their incorporation into regulatory use. However, without a clear strategy to evaluate emerging technologies rapidly and appropriately, the value of these efforts may go unrecognized or may take longer. It is important for the regulatory science field to keep up with the research in these technically advanced areas and to understand the science behind these new approaches. The regulatory field must understand the critical quality attributes of these novel approaches and learn from each other's experience so that workforces can be trained to prepare for emerging global regulatory challenges. Moreover, it is essential that the regulatory community must work with the technology developers to harness collective capabilities towards developing a strategy for evaluation of these new and novel assessment tools.


2021 ◽  
Vol 7 (6) ◽  
pp. 5395-5399
Author(s):  
Chen Yan ◽  
Tianzhi Yao

Objectives: Based on the times analysis, we proposethe world digital currency, proposesthe world digital currency tentative plan. The so-called world digital currency is may distribute one kind of world digital currency, or as its initial digital nationality currency, as well as its initial other form like company or personal digital currency. Then has analyzed the digital currency competition, pointed out the digital currency the competition, is take the national digital currency strategy competition as the foundation, must formulate the good national digital currency strategy, at last we put forward thenew tobacco regulatory science paradigm.


Engineering ◽  
2021 ◽  
Author(s):  
Peng Zhao ◽  
Wenbo Liu ◽  
Jiaxin Tian ◽  
Xinli Shi ◽  
Xiaosong Gu ◽  
...  

Yakhak Hoeji ◽  
2021 ◽  
Vol 65 (5) ◽  
pp. 335-343
Author(s):  
Daewon Kang ◽  
Eun-mi Bae ◽  
Sangyo Kim ◽  
Sanghyun Kim ◽  
Sang-Eun Choi

2021 ◽  
Vol 12 ◽  
Author(s):  
Kirsi M. Kinnunen ◽  
Ariana P. Mullin ◽  
Dorian Pustina ◽  
Emily C. Turner ◽  
Jackson Burton ◽  
...  

Volumetric magnetic resonance imaging (vMRI) has been widely studied in Huntington's disease (HD) and is commonly used to assess treatment effects on brain atrophy in interventional trials. Global and regional trajectories of brain atrophy in HD, with early involvement of striatal regions, are becoming increasingly understood. However, there remains heterogeneity in the methods used and a lack of widely-accessible multisite, longitudinal, normative datasets in HD. Consensus for standardized practices for data acquisition, analysis, sharing, and reporting will strengthen the interpretation of vMRI results and facilitate their adoption as part of a pathobiological disease staging system. The Huntington's Disease Regulatory Science Consortium (HD-RSC) currently comprises 37 member organizations and is dedicated to building a regulatory science strategy to expedite the approval of HD therapeutics. Here, we propose four recommendations to address vMRI standardization in HD research: (1) a checklist of standardized practices for the use of vMRI in clinical research and for reporting results; (2) targeted research projects to evaluate advanced vMRI methodologies in HD; (3) the definition of standard MRI-based anatomical boundaries for key brain structures in HD, plus the creation of a standard reference dataset to benchmark vMRI data analysis methods; and (4) broad access to raw images and derived data from both observational studies and interventional trials, coded to protect participant identity. In concert, these recommendations will enable a better understanding of disease progression and increase confidence in the use of vMRI for drug development.


2021 ◽  
Vol 000 (000) ◽  
pp. 000-000
Author(s):  
Yasser Fouad ◽  
Melissa Palmer ◽  
Minjun Chen ◽  
Arie Regev ◽  
Rajarshi Banerjee ◽  
...  

Author(s):  
Helen I Meissner ◽  
Kriti Sharma ◽  
Rachel J Mandal ◽  
Mary Garcia Cazarin ◽  
Kay L Wanke ◽  
...  

Abstract Introduction This study explores how the emergence of FDA-funded Tobacco Regulatory Science (TRS) research complements and perhaps influenced the direction of tobacco research supported by NIH. Methods New NIH- and FDA-funded tobacco projects awarded in fiscal years (FY) 2011-2020 were identified using internal NIH databases of awarded grants. Project abstracts and research aims were coded by the authors to characterize research domains and tobacco products studied. Results Between FY 2011 and 2020, NIH funded 1032 and FDA funded 322 new tobacco projects. For the years and grant activity codes studied, the number of new NIH tobacco projects declined while FDA’s increased; combined the number of new projects held steady. Much of NIH research included smoking combustibles (43.7%). The most common products in FDA research were cigarettes (74.8%) and e-cigarettes/ENDS (48.1%). Most NIH (58.6%) and FDA (67.7%) projects included research on the determinants of tobacco use. Another area of apparent overlap was health effects (29.5% NIH and 30.1% FDA). Projects unique to NIH included treatment interventions (33.3%), disease pathology/progression (17.8%) and neurobiology (18.9%). A minority of both NIH and FDA projects included populations particularly vulnerable to tobacco product use. Conclusions In total, support for new tobacco research supported by NIH and FDA combined remained steady for the time period covered, though there was a concomitant decline in NIH tobacco projects with the increase in FDA-funded TRS projects for the activity codes studied. Despite apparent overlap in some areas, both NIH and FDA support research that is unique to their respective missions. Implications NIH continues to support tobacco research that falls within and outside of FDA’s regulatory authorities. This research still is needed not only to bolster the evidence base for regulatory decisions at the national and state levels, but also to advance a comprehensive scientific agenda that can inform multiple levels of influence on tobacco control, use and addiction. It will be important to continue monitoring FDA-funded TRS and NIH-funded tobacco research portfolios to ensure that the level of support for and focus of the research is sufficient to address the burden of tobacco-related morbidity and mortality.


Sign in / Sign up

Export Citation Format

Share Document